The objective of this paper is to estimate the risk of reaching well-established disability milestones after withdrawal of natalizumab (NTZ) due to concern about the risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis (MS).

Prosperini, L., Annovazzi, P., Capobianco, M., Capra, R., Buttari, F., Gasperini, C., et al. (2015). Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads. MULTIPLE SCLEROSIS [10.1177/1352458515570768].

Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads

BUTTARI, FABIO;CENTONZE, DIEGO;
2015-02-19

Abstract

The objective of this paper is to estimate the risk of reaching well-established disability milestones after withdrawal of natalizumab (NTZ) due to concern about the risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis (MS).
19-feb-2015
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/26 - NEUROLOGIA
English
Con Impact Factor ISI
Natalizumab; disability; discontinuation; progressive multifocal leukoencephalopathy
Prosperini, L., Annovazzi, P., Capobianco, M., Capra, R., Buttari, F., Gasperini, C., et al. (2015). Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads. MULTIPLE SCLEROSIS [10.1177/1352458515570768].
Prosperini, L; Annovazzi, P; Capobianco, M; Capra, R; Buttari, F; Gasperini, C; Galgani, S; Solaro, C; Centonze, D; Bertolotto, A; Pozzilli, C; Ghezzi...espandi
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/112495
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 20
social impact